A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies.

Yauk, Carole L; Harrill, Alison H; Ellinger-Ziegelbauer, Heidrun; van der Laan, Jan Willem; Moggs, Jonathan; Froetschl, Roland; Sistare, Frank; Pettit, Syril

Yauk, Carole L; Harrill, Alison H; Ellinger-Ziegelbauer, Heidrun; van der Laan, Jan Willem; Moggs, Jonathan; Froetschl, Roland; Sistare, Frank; Pettit, Syril.

Afiliação

Yauk CL; Health Canada, Ontario, K1A 0K9, Canada.
Harrill AH; National Institute of Environmental Health Sciences, Research Triangle, Park, NC, 27709, USA. Electronic address: alison.harrill@nih.gov.
Ellinger-Ziegelbauer H; Bayer AG, Wuppertal, Germany.
van der Laan JW; Medicines Evaluation Board Netherlands, Utrecht, Netherlands.
Moggs J; Novartis Pharma AG, Basel, Switzerland.
Froetschl R; BfArM Federal Institute for Drugs and Medical Devices, Bonn, Germany.
Sistare F; Merck, Kenilworth, NJ, 07033, USA.
Pettit S; Health and Environmental Sciences Institute, Washington, DC, USA.

Regul Toxicol Pharmacol ; 110: 104526, 2020 Feb.

Article em En | MEDLINE | ID: mdl-31726190

Assuntos

Carcinógenos/toxicidade; Neoplasias/induzido quimicamente; Medição de Risco; Toxicogenética; Animais; Testes de Carcinogenicidade; Indústria Química; Indústria Farmacêutica; Humanos

Palavras-chave

Cancer; Cancer risk assessment; Carcinogenicity; Genomics; Risk assessment; Toxicogenomics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinógenos / Medição de Risco / Toxicogenética / Neoplasias Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google